EUVIMEDEUVIMED entdecken
CrossrefInfokarte

DNA-PK interacts with cyclic dinucleotides and inhibits type I interferon responses

Isabelle K. Vila, Yasmine Messaoud-Nacer, Clara Taffoni, Jane Jardine, Roger J. Eloiflin, Adeline Augereau, Soumyabrata Guha, Moritz Schussler, Pierre Le Hars, Joe McKellar, Tamara Carvalho, Jeanne Postal, Morgane Chemarin, Joanna Re, Florence Guivel-Benhassine, Raphaëlle Lopez, Kilian Trillet, Jennifer Barrat, Maximin Serbier, Insaf El Mansouri, Charlotte Luchsinger, George P. Chrousos, Françoise Porrot, Felipe Diaz-Griffero, Olivier Schwartz, Fabien P. Blanchet, Karim Majzoub, Nicolas Bidère, Dimitrios Vlachakis, Nadine Laguette

Journal of Experimental Medicine · 2026-05-04 · 223 (5)

DOI: 10.1084/jem.20251796 ↗
AbstractBibliografische Angaben

Abstract

Inflammatory signal termination is critical for the maintenance of homeostasis. Cyclic dinucleotides (CDNs) are second messengers that trigger inflammatory responses through the activation of the stimulator of IFN genes (STING) signaling platform. No broad-acting direct regulator of intracellular CDNs has been identified in mammals to date. We show that the DNA-dependent protein kinase catalytic subunit (DNA-PKcs), a major DNA damage response actor, directly interacts with the intracellular 2′3′-cGAMP CDN through its kinase domain, tempering STING activation. DNA-PKcs also acts on the 3′3′-cGAMP bacterial CDN and pharmacological STING agonists, impacting their bioactivity and ability to mount optimal antiviral responses. STING agonism has been considered as a therapeutic avenue to alleviate immunosuppression in human pathologies. By uncovering DNA-PKcs as a CDN signaling modulator and CDNs as inhibitors of DNA-PKcs kinase activity, we provide critical insights into CDN regulation, with implications for the development of STING-targeting therapeutics.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →